Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Abstract COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for antibodies targeting relatively conserved regions, individually e...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2023-06-01
|
| coleção: | Nature Communications |
| Acesso em linha: | https://doi.org/10.1038/s41467-023-37826-w |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
